A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects With Diabetic Peripheral Neuropathic Pain

Eliem Therapeutics (UK) Ltd.22 sites in 1 country167 target enrollmentNovember 9, 2020

ConditionsDiabetic Peripheral Neuropathic Pain Diabetic Peripheral Neuropathy

InterventionsETX-018810 Placebo

DrugsETX-018810 Placebo

Overview

Phase: Phase 2
Intervention: ETX-018810
Conditions: Diabetic Peripheral Neuropathic Pain
Sponsor: Eliem Therapeutics (UK) Ltd.
Enrollment: 167
Locations: 22
Primary Endpoint: Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale (PI-NRS)
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.

Detailed Description

ETX-018810 is a new chemical entity that is under development as a non-opioid treatment for chronic pain syndromes. ETX-018810 is a prodrug of palmitoylethanolamide (PEA), an endogenous bioactive lipid that has shown efficacy in a broad range of nonclinical inflammatory and neuropathic pain models and in clinical trials in chronic pain indications, including diabetic peripheral neuropathic pain (DPNP).

Registry

clinicaltrials.gov

Start Date

November 9, 2020

End Date

February 18, 2022

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Eliem Therapeutics (UK) Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The subject is ≥18 and ≤75 years of age at the time of signing ICF.
•The subject has a diagnosis of type 1 or 2 diabetes mellitus.
•The subject has diabetic neuropathy of a symmetrical nature in the lower extremities for ≥6 months to ≤10 years
•The subject reports at least moderate pain intensity
•The subject's onset of neuropathic pain is at least 3 months before the screening visit.
•The subject has used a stable regimen of antidiabetic agents for at least 1 month before the baseline visit or has achieved adequate glycemic control through diet and exercise.
•The subject has clinical laboratory values within normal limits or abnormal values that the investigator deems not clinically significant.
•Sexually active male subjects with female partners of childbearing potential and sexually active female subjects of childbearing potential must agree to practice effective contraception or to remain abstinent during the study and for 4 weeks after the last dose of investigational product
•The subject is capable of giving signed informed consent and agrees to provide authorization for use and release of health records.

Exclusion Criteria

•The subject has pain that cannot be clearly differentiated from or that could interfere with the assessment of DPNP.
•The subject has neurologic and/or circulatory disorders that are unrelated to diabetic neuropathy
•The subject has a history of hypoglycemia that disturbed consciousness or ketoacidosis that required hospitalization within the 3 months before screening.
•The subject has clinically significant and/or unstable renal, hepatic, hematologic, immunologic, inflammatory/rheumatologic, respiratory, or cardiovascular disease that would compromise participation in the study in the judgment of the investigator.
•The subject has any neurological disease that could interfere with participation in the study (eg, Huntington's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, seizures, epilepsy, stroke).
•The subject has an amputation of a lower extremity. Toe amputation is allowed.
•The subject has clinically significant abnormal electrocardiogram (ECG) findings at screening or baseline.
•The subject is likely to require major surgery during the study.
•The subject is pregnant or lactating.
•The subject is unwilling or unable to discontinue current medications for neuropathic pain, including topical agents.

Arms & Interventions

ETX-018810

1000 mg BID for 4 weeks

Intervention: ETX-018810

Placebo

matching placebo BID for 4 weeks

Intervention: Placebo

Outcomes

Primary Outcomes

Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale (PI-NRS)

Time Frame: baseline to Week 4

Change from baseline in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS) a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain).

Secondary Outcomes

Change in the BPI - Interference Scale From Baseline to Week 4(Baseline to Week 4)
Number of Subjects With a CGI-C Response (Defined as "Much Improved" or "Very Much Improved") at Week 4(Week 4)
Change in the BPI-Pain Scale From Baseline to Week 4(Baseline to Week 4)
Number of Subjects With a ≥50% Reduction From Baseline to Weeks 1, 2, 3, and 4 in the Weekly Average of the Daily Pain Score(Baseline to Weeks 1, 2, 3 and 4)
Number of Subjects With a ≥30% Reduction From Baseline to Weeks 1, 2, 3, and 4 in the Weekly Average of the Daily Pain Score(Baseline to Weeks 1, 2, 3 and 4)
Change in the Weekly Average of the Daily Sleep Score on the DSIS From Baseline to Weeks 1, 2, 3, and 4(Baseline to Weeks 1, 2, 3 and 4)
Change in the Weekly Average of the Daily Pain Score From Baseline to Weeks 1, 2, and 3(Baseline to Weeks 1, 2 and 3)
Number of Subjects With a PGI-C Response (Defined as "Much Improved" or "Very Much Improved") at Week 4.(Week 4)
Change in the Daily Amount of Acetaminophen Use From Baseline to Week 4(Baseline to week 4)